Table 1 Characteristics of the patients in the exploration and validation cohorts
Patient characteristic | Initial exploration cohort (n = 46) | Clinical validation cohort (n = 147) |
|---|---|---|
Gender (male/female) | 34*/12* | 79*/68* |
Age (years) | 61.5 ± 8.8 [43–81] | 59.4 ± 12.1 [20–87] |
Weight (kg) | 67.0 ± 11.2 [46.3–90.7] | 63.8 ± 11.7 [38.3–105.0] |
Height (cm) | 166.4 ± 7.4 [152.6–184.4] | 164.3 ± 8.7 [139.0–185.2] |
Blood glucose | 5.7 ± 1.1 [4.1–9.1] | 5.9 ± 1.4 [3.7–10.8] |
BMI (kg/m2) | 24.1 ± 3.5 [17.4–33.1] | 23.6 ± 3.6 [15.5–36.0] |
Injected dose (MBq) | 125.9 ± 21.1 [85.1–174.4] | 119.7 ± 22.3 [73.1–216.0] |
Injected dose per unit weight (MBq/kg) | 1.88 ± 0.09 [1.73–2.15] | 1.88 ± 0.10 [1.67–2.18] |
Uptake time (min) | 64.7 ± 17.2 [40–106] | 73.4 ± 17.5 [40–115] |
Lesion counts (lesion/patient) | 1.6 ± 0.8 [1–4] | 1.6 ± 1.1 [1–8] |
Lesion short diameter (mm) | 15.8 ± 12.8 [4.9–85.5] | 20.8 ± 18.6 [4.0–120.4] |